In particular, it has been reported that tamoxifen-treated ER+ breast cancers often present high BCL-2 and BCL-xL expression [52], and that tumors harboring elevated MCL-1 protein expression exert poorer prognosis [53]. This evidence concerns the gene BCL2 and breast cancer.